Celltrion Pharm

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 183.6M pre-tax income sensitivity to 10% USD exchange rate change at FY2025 end
• • KRW 142B variable-rate borrowings exposed to interest rate risk with ±KRW 1.42B profit/loss impact per 1% rate change

Management Discussion & Analysis

• • Revenue KRW 536.4B (+12.3% YoY); Operating profit KRW 56.1B (+50.7%); Net income KRW 38.8B (+76.4%)
• • Bio-pharmaceutical segment sales KRW 130.6B, up 50.8% YoY; driven by strong growth beyond Ramsima

Business Overview

• • Pharmaceutical revenue KRW 536.4B in FY2025, 12.3% increase YoY driven by chemical drugs KRW 200.6B (+7.8%) and biosimilars KRW 130.6B (+50.8%)
• • PFS (Prefilled Syringe) biosimilar production line certified by US and EU GMP, located in Ochang facility with 2,315㎡ area

What are the latest Celltrion Pharm DART filings in 2026?

Celltrion Pharm (KRX code 068760) has filed an annual report on March 16, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Celltrion Pharm file its most recent annual report?

Celltrion Pharm filed its most recent annual report on March 16, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Celltrion Pharm's KRX stock code?

Celltrion Pharm's KRX stock code is 068760. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 068760 to look up all Celltrion Pharm disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Celltrion Pharm file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Celltrion Pharm.

Where can I find Celltrion Pharm financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Celltrion Pharm annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.